[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong growth in the first nine months – outlook for 2021 raised
October 20, 2021 01:00 ET | F. Hoffmann-La Roche Ltd
Basel, 20 October 2021 Group sales up 8%1 at constant exchange rates (CER); 6% in Swiss francsPharmaceuticals Division sales grow 5% in the third quarter and...
[Annonce événementielle selon l’art. 53 RC] Roche annonce une forte croissance de son chiffre d’affaires sur les neuf premiers mois de l’année – prévisions pour 2021 révisées à la hausse
October 20, 2021 01:00 ET | F. Hoffmann-La Roche Ltd
Bâle, le 20 octobre 2021 Le chiffre d’affaires consolidé s’inscrit en hausse de 8%1 à taux de change constants (TCC) et de 6% en francs suisses.Le chiffre d’affaires de la division...
[Ad hoc-Mitteilung gemäss Art. 53 KR] Roche mit starkem Wachstum in den ersten neun Monaten 2021 – Ausblick für das Gesamtjahr erhöht
October 20, 2021 01:00 ET | F. Hoffmann-La Roche Ltd
Basel, 20. Oktober 2021                                                 Konzernverkäufe steigen um 8%1 zu konstanten Wechselkursen (CER); 6% in Schweizer FrankenVerkäufe der Division Pharma wachsen...
logo.png
US FDA approves Roche’s Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer
October 15, 2021 12:30 ET | F. Hoffmann-La Roche Ltd
Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant settingApproval is based on the Phase III IMpower010 study showing adjuvant Tecentriq improved disease-free...
logo.png
Roche announces PathAI collaboration for artificial intelligence-based digital pathology applications for improved patient care
October 15, 2021 01:00 ET | F. Hoffmann-La Roche Ltd
Artificial Intelligence technology shows promise in advancing pathology imaging, which can benefit cancer patients through more precise diagnosis leading to targeted treatment.Collaboration with...
logo.png
New four-year data show Roche's ENSPRYNG significantly reduces debilitating relapses in people with neuromyelitis optica spectrum disorder
October 14, 2021 01:03 ET | F. Hoffmann-La Roche Ltd
New data demonstrate ENSPRYNG’s robust and sustained longer-term efficacy in preventing relapses in people with neuromyelitis optica spectrum disorder (NMOSD) More than 70% of people treated with...
logo.png
Roche’s Gazyvaro shorter 90-minute infusion time approved in Europe for people with previously treated or untreated follicular lymphoma
October 14, 2021 01:00 ET | F. Hoffmann-La Roche Ltd
Short duration infusion of Gazyvaro® (obinutuzumab) is administered with a target infusion time of 90 minutes, compared to the current standard infusion time of approximately three to four...
logo.png
Data up to 8-years for Roche’s OCREVUS (ocrelizumab) show early and ongoing treatment significantly reduced risk of requiring a walking aid in relapsing multiple sclerosis and disability progression in primary progressive multiple sclerosis
October 13, 2021 01:00 ET | F. Hoffmann-La Roche Ltd
35% reduction in risk of needing a walking aid in relapsing multiple sclerosis (RMS) after 7.5 years vs. initiation 2 years later in Phase III open-label extension (OLE)29% reduction in 48-week...
logo.png
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s anti-amyloid beta antibody gantenerumab granted FDA Breakthrough Therapy Designation in Alzheimer’s disease
October 08, 2021 11:40 ET | F. Hoffmann-La Roche Ltd
Gantenerumab is an investigational antibody in Phase III development for early Alzheimer's disease (AD)Gantenerumab is the first and only anti-amyloid antibody being investigated for subcutaneous...
logo.png
Roche to present new data on OCREVUS in multiple sclerosis and ENSPRYNG in neuromyelitis optica spectrum disorder at ECTRIMS 2021
October 05, 2021 01:00 ET | F. Hoffmann-La Roche Ltd
OCREVUS (ocrelizumab) data to show sustained reduction in disability progression through 8 years for primary progressive multiple sclerosis (PPMS) and 7.5 years for relapsing MS (RMS) Long-term safety...